Prosecution Insights
Last updated: April 19, 2026
Application No. 18/766,429

COMPOSITIONS AND METHODS FOR THE TREATMENT OF PRESBYOPIA

Non-Final OA §Other
Filed
Jul 08, 2024
Examiner
DIAMOND, ALAN D
Art Unit
3991
Tech Center
3900
Assignee
Lenz Therapeutics Operations Inc.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
2y 5m
To Grant
79%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
137 granted / 192 resolved
+11.4% vs TC avg
Moderate +8% lift
Without
With
+7.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
21 currently pending
Career history
213
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
22.9%
-17.1% vs TC avg
§102
6.0%
-34.0% vs TC avg
§112
35.0%
-5.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 192 resolved cases

Office Action

§Other
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Reissue Applications For reissue applications filed on or after September 16, 2012, all references to 35 U.S.C. 251 and 37 CFR 1.172, 1.175, and 3.73 are to the current provisions. This application, filed July 8, 2024, is a reissue of U.S. Patent 11,179,327 (hereinafter the ‘327 patent), which issued from U.S. application Serial No. 16/106,730 (the ‘730 application) with claims 1-15 on November 23, 2021. Reissue Declaration The reissue declaration by assignee filed 07/08/2024 is defective (see 37 CFR 1.175 and MPEP § 1414) because of the following: The reissue declaration is defective because it improperly lists Lee Nordan as a co-inventor. Lee Nordan is the person removed as a co-inventor from the ‘327 patent by the instant reissue application. As noted in MPEP 1414.01, a reissue declaration must identify the inventor. Non-inventor(s) cannot be listed on the reissue declaration. A new reissue declaration identifying Gerald Horn as the sole inventor is required. Claims 1-15 are rejected as being based upon a defective reissue declaration under 35 U.S.C. 251 as set forth above. See 37 CFR 1.175. The nature of the defect(s) in the reissue declaration is set forth in the discussion above in this Office action. Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALAN D DIAMOND whose telephone number is (571)272-1338. The examiner can normally be reached Monday through Thursday 5:30 am to 3:00 pm, and Fridays from 5:30 am to 9:30 am. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Patricia Engle can be reached at571-272-6660. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Signed: /ALAN D DIAMOND/Patent Reexamination Specialist Central Reexamination Unit 3991 Conferees: /JOSEPH R KOSACK/ /Patricia L Engle/Patent Reexamination Specialist SPRS, Art Unit 3991 Central Reexamination Unit 3991
Read full office action

Prosecution Timeline

Jul 08, 2024
Application Filed
Feb 19, 2026
Non-Final Rejection — §Other (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent RE50811
Rapid Imaging Systems and Methods for Facilitating Rapid Radiation Therapies
2y 5m to grant Granted Mar 10, 2026
Patent RE50805
SINGLE-LAYER ORAL DOSE OF NEURO-ATTENUATING KETAMINE
2y 5m to grant Granted Feb 24, 2026
Patent RE50799
JAK1 SELECTIVE INHIBITORS AND USES THEREOF
2y 5m to grant Granted Feb 17, 2026
Patent RE50790
INK COMPOSITION, INK JET RECORDING METHOD, METHOD FOR PRODUCING PLANOGRAPHIC PRINTING PLATE AND PLANOGRAPHIC PRINTING PLATE
2y 5m to grant Granted Feb 10, 2026
Patent RE50776
INHIBITORS OF CYCLIN-DEPENDENT KINASES
2y 5m to grant Granted Feb 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
79%
With Interview (+7.6%)
2y 5m
Median Time to Grant
Low
PTA Risk
Based on 192 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month